Biofidelity to Launch Enspyre Technology
Biofidelity is launching Enspyre, a novel target enrichment technology that significantly enhances NGS efficiency.
Read MorePosted by Chris Wolski | Feb 20, 2025 | Molecular Diagnostics |
Biofidelity is launching Enspyre, a novel target enrichment technology that significantly enhances NGS efficiency.
Read MorePosted by Chris Wolski | Feb 6, 2025 | Lung Cancer |
Scientists have developed a low-cost, fast-response sensor capable of detecting lung cancer biomarkers from a blood sample in just 40 minutes.
Read MorePosted by Andy Lundin | Jan 22, 2025 | Unknown Origin & Other Cancer Types |
A biomarker-based algorithm combined with a noninvasive test identifies those at risk for esophageal cancer or precancerous conditions.
Read MorePosted by Chris Wolski | Jan 15, 2025 | Miscellaneous |
Following a People-to-People trip to Cuba, CLP Chief Editor Chris Wolski gained a more nuanced view of the Cuban healthcare system.
Read MorePosted by Andy Lundin | Jan 15, 2025 | Lung Cancer, Molecular Diagnostics |
A new demonstrates the high sensitivity of the NeXT Personal test for detecting ctDNA in early-stage lung cancer.
Read More